Projects

Head of the Department of Cardiovascular Physiology and Pathophysiology, Scientific Secretary
doc. RNDr. Monika Barteková, PhD.

International

Current
  • EUropean network to tackle METAbolic alterations in HEART failure
    Program: COST
    Duration: 18. 10. 2023 – 17. 10. 2027
  • Bridging the gap between cardiac and vascular regeneration
    Program: Horizon Europe
    Duration: 1. 1. 2024 – 31. 12. 2026
Finished
  • Improving preclinical assessment of cardioprotective therapies
    Program: COST
    Duration: 14. 9. 2022 – 31. 10. 2023
  • Catalysing transcriptomic research in cardiovascular disease
    Program: COST
    Duration: 3. 10. 2018 – 2. 10. 2022
  • New Frontiers in Basic Cardiovascular Research 2022
    Program: International Visegrad Fund (IVF)
    Duration: 1. 1. 2021 – 30. 6. 2022
  • Realising the therapeutic potential of novel cardioprotective therapies
    Program: COST
    Duration: 19. 10. 2017 – 18. 4. 2022
  • Study of endogenous cardioprotective mechanisms against myocardial ischemia
    Program: Inter-academic agreement
    Duration: 1. 1. 2009 – 31. 12. 2014
  • Study of the adaptive mechanisms in the heart during ischemic injury: novel possibilities of cardioprotection.
    Program: Inter-academic agreement
    Duration: 1. 6. 2010 – 30. 5. 2011
  • Activation of cellular adaptive processes as a potential target of cardiac protection against ischaemic injury
    Program: Inter-governmental agreement
    Duration: 1. 1. 2008 – 1. 12. 2009

National

Current
  • Novel antidiabetic/antiobesty drugs as innovative pharmacotherapeutic tools for cardioprotection in experimental model of type 2 diabetes
    Program: VEGA
    Duration: 1. 1. 2024 – 31. 12. 2027
  • Cardiovascular protection mediated by alpha 1 AMPK against metabolic syndrome-mediated endothelial dysfunction - identifying new risk factors
    Program: SRDA
    Duration: 1. 7. 2023 – 30. 6. 2027
  • New aspects of cardioprotection by natural antioxidants: role of ageing and lifestyle-related comorbidities
    Program: SRDA
    Duration: 1. 7. 2022 – 30. 6. 2026
  • Necroptotic and pleiotropic effects of RIP3 kinase acting as a convergent point in cardiac cell loss: understanding the basic mechanisms in the ischemic heart with or without metabolic stress as a tool for designing therapeutic approaches.
    Program: SRDA
    Duration: 1. 7. 2021 – 30. 6. 2025
Finished
  • Study of new mechanisms of cardioprotection against ischemia-reperfusion injury of the heart: role of extracellular vesicles, non-coding RNAs and impact of metabolic co-morbidities on these mechanisms
    Program: VEGA
    Duration: 1. 1. 2020 – 31. 12. 2023
  • The role of macroautophagy and chaperone-mediated autophagy (CMA) in the responses and adaptation of animal cells to doxorubicin-induced effects
    Program: VEGA
    Duration: 1. 1. 2021 – 31. 12. 2023
  • The role of matrix metalloproteinases in pathophysiology of cardiovascular system diseases and their relation to cellular redox signaling.
    Program: SRDA
    Duration: 1. 7. 2019 – 30. 6. 2023
  • Research of magnetic forms of iron in development of cardiovascular diseases and behavioural disorders
    Program: SRDA
    Duration: 1. 7. 2017 – 30. 6. 2021
  • Role of Nrf2 signaling pathway in responses of cardiac cells to pathological conditions
    Program: VEGA
    Duration: 1. 1. 2018 – 31. 12. 2020
  • The role of extracellular vesicles in inter-organ communication related to remote cardioprotection
    Program: VEGA
    Duration: 1. 1. 2016 – 31. 12. 2019
  • Matrix-metalloproteinases, microRNAs and deformability of erythrocytes as a novel diagnostic and predictive biomarkers of heart failure
    Program: VEGA
    Duration: 1. 1. 2014 – 31. 12. 2017
  • Molecular mechanisms involved in the effects of doxorubicin in rats with developed hypertension and ways of modulation of of these effects of doxorubicin by quercetin.
    Program: VEGA
    Duration: 1. 1. 2015 – 31. 12. 2017
  • Chemoenzymatic synthesis and evaluation of biological activities of natural glycophenols and their analogues
    Program: SRDA
    Duration: 1. 10. 2013 – 30. 9. 2017
  • The effect of chronic stress on cell proliferation in the heart
    Program: VEGA
    Duration: 1. 1. 2012 – 31. 12. 2015
  • Mechanisms involved in the effects of doxorubicin on animal cells and searching for possibilities of modulation of doxorubicin-induced effects.
    Program: VEGA
    Duration: 1. 1. 2012 – 31. 12. 2014
  • Modulatory effect of lifestyle-related risk factors on the mechanisms of subcellular adaptation to myocardial ischemia
    Program: VEGA
    Duration: 1. 1. 2011 – 31. 12. 2013
  • Investigation of molecular mechanisms involved in doxorubicin-induced cardiomyopathy and possibilities to modulate the cardiotoxicity of doxorubicin.
    Program: VEGA
    Duration: 1. 1. 2009 – 31. 12. 2011
  • The role of matrix metalloproteinases in cardiac remodelation in rats with dietary-induced insulin resistance.
    Program: VEGA
    Duration: 1. 1. 2007 – 31. 12. 2009
  • -
    Program: VEGA
    Duration: 1. 1. 2007 – 1. 12. 2009
  • Role of bioflavonoids in prevention of social stress-induced hypertension
    Program: SRDA
    Duration: 1. 1. 2005 – 31. 12. 2007
  • Interactions of cell signaling mechanisms in the processes of myocardial ischemic injury and endogenous cardioprotection
    Program: VEGA
    Duration: 1. 1. 2005 – 1. 12. 2007
Employees